zum Inhalt
Header Image

02: Cancer research and cancer care – Construction and reality

Seminar / Seminar
in englischer Sprache

Overall, cancer is one of the most frequent causes of death, and the impact of this disease on society is enormous. Fortunately, cancer research is one of the most dynamic fields in medical research, and significant resources, both public and industrial, are invested into the field. Tremendous progress has been made in the diagnosis and treatment of many cancers, and there is rarely another field in medical research where breakthrough technology – mostly from molecular biology – has been translated to actual benefit as rapidly as in cancer medicine.

Despite significant recent improvements in treatment modalities and outcome several problem fields in cancer research persist or unfold: How can we further improve the results of early detection and treatment? Is there cure for cancer? And if so – what are the implications of this vision for society? How are we measuring patient benefit in a holistic sense? Since cost of cancer research is increasing exponentially, what is the actual value of further progress for society?

In addition, research progress is not the only issue in the field of modern cancer medicine: Improving cancer care in a multidimensional sense of the word is considered an equally important subject, with several unresolved questions: What are the psychological and social consequences of this disease even if hope can be offered by medicine? How to cope with the socioeconomic fall-out for patients affected and their families? How to provide equal access to modern medical achievements in the existing diversity of health care systems throughout Europe? What are the implications of an integrated view of cancer care on society?

In this seminar, these main questions and related aspects of the subject will be discussed, and potential answers developed together with participants and internationally renowned guest speakers from several fields in order to provide a multi-dimensional perspective on one of the most exciting fields in modern medicine.

Professor, Department of Oncology-Pathology, Karolinska Institutet, Stockholm
President, Colon Cancer Support Group, Vienna
Professor and Deputy Director, Department of Surgery, Medical University of Vienna
Professor of Medical Oncology; Director, Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, University of Manchester

Ph.D. Jonas BERGH

Professor, Department of Oncology-Pathology, Karolinska Institutet, Stockholm

Medical School, Umeå and Uppsala University, Sweden (MD) Internship (Internal Medicine, Anaesthesiology, Surgery, Psychiatry, GP) Uppsala University Hospital, license to practice medicine in Sweden PhD in Pathology/Tumour biology, University of Uppsala and 1982-1988 Clinical training and Education in Pathology and Oncology Board certified in Pathology in Sweden; Board certified in Oncology, includes Medical Oncology and Radiotherapy Associate Professor in Experimental Oncology, Uppsala University Licence to practice medicine, specialist in Clinical Oncology UK 2/9, 2009 Senior registrar, assistant consultant and consultant, Dept of Oncology, University Hospital, Uppsala, Sweden Consultant, Karolinska University Hospital, Radiumhemmet (20% from October 2009) Professor of clinical and molecular oncology, Karolinska Institutet Professor of Oncology (Mimi Althainz´ donation, the first chair in radiotherapy, later transferred to oncology in Sweden), Karolinska Institutet Scientific Director Karolinska Oncology and Medical Director for the Clinical Trial Unit Chairman for the Oncology-Haematology expert group (LÄKSAK), Stockholm County Council Professor of Breast Oncology, Paterson Institute/Manchester University
since 1999
since 2008
since 2009
since 2009


President, Colon Cancer Support Group, Vienna

Key Account Manager, Magazin "Society" sowie PR und Eventorganisation
  Ausbildung zur MTA (Ord. Prof. Dr. Thurnher, Prof. Dr. Olbert)
seit 1999
  Herausgeberin, Magazin "Forum Darmkrebs"
  Veranstalterin der "Tage der Darmgesundheit"

Dr. Michael GNANT

Professor and Deputy Director, Department of Surgery, Medical University of Vienna

Medizinstudium, Universität Wien Auslandsstudium Universität München, Deutschland Promotion zum Dr. med. univ. Koordinator, Abteilung f. Transplantation (1. Chirurgische Universitätsklinik) Universitätsassistent, 1. Chirurgische Universitätsklinik. Ausbildung in Allgemeinchirurgie mit Rotation in Gefäßchirurgie, Unfallchirurgie, Intensivmedizin, Gerichtliche Medizin. Ausbildung in Medizinischer und experimenteller Onkologie an der Universitätsklinik für Innere Medizin. Universitätslektor an der medizinischen Fakultät Facharzt für Chirurgie Ernennung zum Oberarzt der Universitätsklinik für Chirurgie Leiter, Arbeitsgruppe Mammakarzinom Leiter, Arbeitsgruppe Experimentelle Chirurgische Onkologie Auslandsaufenthalt am National Cancer Institute / NIH, Bethesda, USA / Surgery Branch (Chief: Dr. Steven Rosenberg) Rückkehr nach Wien Lehrbefugnis im Fach Chirurgie; Verleihung des Titels Außerordentlicher Universitätsprofessor Leiter, Arbeitsgruppe Pankreaskarzinom Station 21D/Klinik für Chirurgie: bettenführender Oberarzt Reihung als "primo et unico loco" durch Berufungskommission/Fakultät für die neugeschaffene Professur für Chirurgisch-exp. Onkologie der Medizinischen Fakultät der Universität Wien
seit 1996
seit 1996


Professor of Medical Oncology; Director, Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, University of Manchester

 Anthony Howell is Professor of Medical Oncology and is the Director of the Breakthrough Breast Cancer Research Unit, University of Manchester. Formerly he was Chairman of the UKCCCR - United Kingdom Coordinating Committee on Cancer Research, the British Breast Group and the Manchester Breast Centre, was the Research and Development Director of The Christie NHS Foundation Trust and the Cancer Research Network. His interests are the endocrine therapy and biology of the breast and breast cancer with a particular interest in prevention. He has published over 500 papers mainly in these areas. He is also principal investigator on several clinical trials, including those developing 'pure' antioestrogens.


Timetable einblenden
kategorie: Alle Plenary Seminar
Genre : Alle Panel Seminar